Navigation Links
Revised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance
Date:9/3/2014

reports are presented in the announcement titled "AbbVie Raises Outlook for 2014" issued on June 23, 2014 and "AbbVie Reports Second-Quarter 2014 Financial Results" issued on July 25,2014 available on AbbVie's website at: www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents.

In accordance with Rule 30.4 of the Code, a copy of this announcement will be available on AbbVie's website at www.abbvieinvestor.com.

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories.  The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.  AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.  For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com.  Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

No Offer or Solicitation
This release is provided for informational purposes only and does not constitute an offer to sell, or an invitation to subscribe for, purchase or exchange, any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance, exchange or transfer of the securities referred to in this release in any jurisdiction in contravention of applicable law.

Additional Information and Where to Find it
In furtherance of the combination, AbbVie Private Limited ("New Abb
'/>"/>

SOURCE AbbVie
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. International Probiotics Association Excited To Learn The FDA Has Decided To Issue A New, Revised NDI Draft Guidance
2. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
3. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
4. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
5. WuXi PharmaTech Schedules Second-Quarter 2012 Earnings Release
6. Life Technologies Sets 2nd Quarter 2012 Earnings Release Date for Tuesday, July 31, 2012
7. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
8. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations
9. Cambrex Reschedules Third Quarter 2012 Financial Results and Earnings Call Date to November 5, 2012
10. Sigma-Aldrich Announces Q4 2012 Earnings Conference Call
11. Zynga, Inc. Fourth-Quarter Earnings and Sales Topped Wall Street Estimates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... basic Naltrexone HCL information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
(Date:10/30/2014)... York, NY (PRWEB) October 30, 2014 ... plan for its ICH Stability Testing and Package Test ... this investment centers on a dramatic increase in environmental ... volume of stability, storage and aging samples to be ... stage of this major capital expenditure has already taken ...
(Date:10/30/2014)... Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a company overview at the Nomura ... ET in Boston, MA. ... the "Investors & Media" section of the Company,s website, ... website within 48 hours and will be archived for a ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... Oct. 26, 2011 Accuray Incorporated (Nasdaq: ... announced today significant momentum in global adoption of its ... are now in use at leading cancer centers throughout ... image-guided, intensity-modulated radiation therapy (IG-IMRT) for routine radiation therapy ...
... poison from this smorgasbord of recent salmonella outbreaks in ... That,s in 2011 alone, and the list goes on, ... Prevention. But perhaps not for long, thanks to a ... of salmonella bacteria before contaminated food or animals reach ...
... ProteinSimple today announced the launch of the ... Imaging platforms. Bot1 automates analysis of protein aggregates and ... the IBC,s 11th Annual Formulation Strategy for Protein Therapeutics ... Protein therapeutic manufacturers must monitor microscopic particles and ...
Cached Biology Technology:Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 2Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 3Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 4ProteinSimple Automates Aggregation Analysis 2
(Date:10/30/2014)... NY, October 30, 2014—Oligonucleotide-based therapeutics present unique challenges ... cause reproductive and developmental harm. New consensus guidelines ... combined chemical and biological characteristics of these novel ... , a peer-reviewed journal from Mary Ann ... free on the Nucleic Acid Therapeutics ...
(Date:10/30/2014)... | Heidelberg, 30 October 2014 Biological membranes are ... understanding of adsorption of solution ions onto lipid ... Now, a new study provides a quantitative description ... solution ions. Joanna Kotyńska and Zbigniew Figaszewski from ... of a study describing these findings, just published ...
(Date:10/29/2014)... their hair as a consequence of chemotherapy will benefit ... scalp cooling technology that prevents hair loss. , The ... by global scalp cooling manufacturing company, Paxman Coolers, of ... of the University of Huddersfield. , The research will ... a background in the pharmacology of cancer treatment, which ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Ion adsorption matter in biology 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... Marine Board-ESF published its 13th Position Paper, which presents ... needed to assess the effects of anthropogenic sound upon ... Board Position Paper 13 results from the activities and ... marine mammals convened at the joint European Marine Board ...
... gorgeously-decorated fish which throng Australia,s coral reefs and help earn ... be written in their genes. Of particular importance may ... re-colonise regions of reef devastated by global warming and other ... says Dr Line Bay of the ARC Centre of Excellence ...
... base and,revenues, JERICHO, N.Y., Sept. 29 ... it has executed a non-binding,Letter of Intent with ... controlling interest in Biometric Solutions, Inc. The terms ... Biometric Solutions LLC is a premiere engineering firm, ...
Cached Biology News:Effects of anthropogenic sound on marine mammals -- a research strategy 2Fishy future written in the genes 2Fishy future written in the genes 3bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC 2bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC 3
Pronase Reagent...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: